Patents Assigned to Aventis Pharma S.A.
  • Oligonucleotides which inhibit expression of the OB-RGRP protein
    Patent number: 7884084
    Abstract: The present application relates to antisense oligonucleotides which inhibit expression of the OB-RGRP protein and to uses thereof for preventing and/or treating leptin-related pathological conditions. It also relates to a method for detecting compounds which modify the interaction between proteins of the OB-RGRP family and the leptin receptor. This detection may be carried out by measuring the energy transfer between fusion proteins composed of these proteins and of energy-donor and -acceptor proteins.
    Type: Grant
    Filed: February 9, 2004
    Date of Patent: February 8, 2011
    Assignees: Aventis Pharma S.A., Institut National de la Sante Et de la Recherche Medicale, Centre National de la Rechercher Scientifique
    Inventors: Ralf Jockers, Cyril Couturier, Eugen Uhlmann
  • Substituted thieno[2,3-c]pyrazoles, process for preparing them, compositions containing them, and use thereof
    Patent number: 7884123
    Abstract: Compounds of formula (I), wherein R1 and R3 have the meanings given in the description, said compounds being in all isomeric forms; and salts thereof; processes for the preparation of the compounds and intermediates; compositions containing them, and the use thereof as medicaments, particularly as anti-cancer agents.
    Type: Grant
    Filed: May 23, 2007
    Date of Patent: February 8, 2011
    Assignee: Aventis Pharma S.A.
    Inventors: Jean-Christophe Carry, Gilles Doerflinger, Antony Bigot, Dominique Barbalat-Damour, François Clerc, Arielle Genevois-Borella, Baptiste Ronan, Hervé Minoux, Claude Barberis, Yves Janin
  • Modified yeasts and uses thereof, in particular for producing steroid derivatives
    Patent number: 7879592
    Abstract: The present invention relates to novel yeast strains, methods and genetic constructs for their preparation, and their use for the synthesis or modification of steroidal compounds. More particularly, the invention describes strains having a reduced 20?HSD type activity, in particular by modifying the GCY1 and/or YPR1 genes. The yeast strains of the invention make it possible to improve the efficiency of the synthesis or to increase the selectivity or the yields of the method, as well as the quality of the final product. The strains, methods and compounds of the invention are useful in the search for, the development and the production of products with therapeutic or prophylactic activity, in humans or animals, in particular of steroidal derivatives.
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: February 1, 2011
    Assignee: Aventis Pharma S.A.
    Inventors: Bruno Dumas, Gilles Cauet, Tilman Achstetter, Eric Degryse
  • Taste Masked Oral Composition of Telithromycin
    Publication number: 20110020442
    Abstract: The invention relates to an oral compositions comprising telithromycin that have taste masking properties, a process for the preparation thereof, and methods of using the composition.
    Type: Application
    Filed: October 7, 2010
    Publication date: January 27, 2011
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Philippe Becourt, Nicoletta Cioloca, Luigi Boltri, Stefano De Luigi Bruschi, Luigi Giovanni Mapelli, Leonardo Rabaglia, Detlev Schwabe
  • METHOD OF USING ENOXAPARIN FOR REDUCING THE RISK OF DEATH IN ACUTELY ILL MEDICAL PATIENTS
    Publication number: 20100331746
    Abstract: The invention relates to a method of using of enoxaparin for reducing the risk of death in acutely ill medical patients.
    Type: Application
    Filed: February 19, 2010
    Publication date: December 30, 2010
    Applicant: AVENTIS PHARMA S.A.
    Inventor: Bruno DESLANDES
  • NOVEL TAXOID-BASED COMPOSITIONS
    Publication number: 20100311825
    Abstract: The disclosure relates to novel taxoid-based compositions comprising injectable formulations of these derivatives in the form of an emulsion.
    Type: Application
    Filed: April 9, 2010
    Publication date: December 9, 2010
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Patricia RORTAIS, Carine GACHON
  • Method of cancer treatment by p53 protein control
    Patent number: 7837991
    Abstract: Method of cancer treatment by controlling cellular p53 protein levels. The invention concerns, in particular, the use of a compound capable of modulating calpaine activity.
    Type: Grant
    Filed: March 1, 2004
    Date of Patent: November 23, 2010
    Assignee: Aventis Pharma, S.A.
    Inventors: Serge Carillo, Jean-Marie Blanchard, Marc Piechaczyk
  • Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors
    Patent number: 7825115
    Abstract: The disclosure relates to a cyclic urea compound of formula I: as defined herein, to the process for its preparation, pharmaceutical composition comprising it and its pharmaceutical use as an inhibitor on a protein kinase. Thus, the compound of formula I is useful for preventing or treating a physiological disorder capable of being modulated by inhibiting the activity of a protein kinase, such as a solid tumor.
    Type: Grant
    Filed: January 10, 2008
    Date of Patent: November 2, 2010
    Assignee: Aventis Pharma S.A.
    Inventors: Marcel Patek, Anil Nair, Augustin Hittinger, Conception Nemecek, Daniel Bond, Greg Harlow, Herve Bouchard, Jacques Mauger, Jean-Luc Malleron, Mark Palermo, Fahad Al-Obeidi, Thomas Faitg, Hartmut Strobel, Sven Ruf, Kurt Ritter, Youssef El-Ahmad, Dominique Lesuisse, Didier Bénard
  • Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
    Patent number: 7812007
    Abstract: Alkali and alkali-earth metal salts of polysaccharides derived from heparin, their method of preparation and the pharmaceutical compositions containing them.
    Type: Grant
    Filed: April 1, 2005
    Date of Patent: October 12, 2010
    Assignee: Aventis Pharma S.A.
    Inventors: Christelle Pecquet, Elisabeth Perrin, Christian Viskov
  • NOVEL BIS-AZAINDOLE DERIVATIVES, PREPARATION AND PHARMACEUTICAL USE THEREOF AS KINASE INHIBITORS
    Publication number: 20100256141
    Abstract: Disclosed are compounds of formula (I): wherein R1, R2, R3, R4, and R5 have the meanings given in the description, and to salts thereof, pharmaceutical compositions comprising said compounds and the use thereof as protein kinase inhibitors.
    Type: Application
    Filed: June 23, 2010
    Publication date: October 7, 2010
    Applicant: Aventis Pharma S.A.
    Inventors: Conception NEMECEK, William A. METZ, Sylvie WENTZLER, Dominique LESUISSE, Youssef EL-AHMAD
  • OLIGOSACCHARIDES, PREPARATION METHOD AND USE THEREOF, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
    Publication number: 20100249061
    Abstract: The invention relates to oligosaccharides, the preparation method and use thereof, and pharmaceutical compositions containing same. More specifically, the invention relates to oligosaccharides which can be used for the treatment of cancer and, in particular, to prevent and inhibit the formation of metastases. The inventive oligosaccharides can be used, for example, during early breast, lung, prostate, colon or pancreatic cancer. The oligosaccharides can be administered subcutaneously, orally or intravenously. Moreover, said oligosaccharides can be used alone or together with other anticancer agents, e.g. cytotoxics such as docetaxel or paclitaxel.
    Type: Application
    Filed: January 21, 2010
    Publication date: September 30, 2010
    Applicant: Aventis Pharma S.A.
    Inventors: Christian VISKOV, Pierre MOURIER
  • Bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
    Patent number: 7786114
    Abstract: Compounds of formula (I): wherein R1, R2, R3, R4, and R5 have the meanings given in the description, and to salts thereof, pharmaceutical compositions comprising said compounds and the use thereof as protein kinase inhibitors.
    Type: Grant
    Filed: March 28, 2007
    Date of Patent: August 31, 2010
    Assignee: Aventis Pharma S.A.
    Inventors: Conception Nemecek, William A. Metz, Sylvie Wentzler, Dominique Lesuisse, Youssef El-Ahmad
  • Lipid derivatives of aminoglycosides
    Patent number: 7772003
    Abstract: Transfecting compounds which include an aminoglycoside linked to a lipid via a spacer, and their polyguanidylated derivatives are provided. These compounds are useful for the in vitro, ex vivo, or in vivo transfection of nucleic acids into various cell types.
    Type: Grant
    Filed: August 28, 2002
    Date of Patent: August 10, 2010
    Assignees: Aventis Pharma S.A., Centre National de la Recherche Scientifique (CNRS), Institut Nationale de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Jean-Marie Lehn, Pierre Lehn, Jean-Pierre Vigneron
  • Cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
    Patent number: 7759379
    Abstract: The invention relates to compounds of formula (I): in which R1, R2, L1, X, R3, A, R4, R4?, R4?, R4??, R5, Y and L2 are as herein defined, salts and prodrugs thereof, to their use as protein kinase inhibitors, and to methods of treating diseases comprising adminstration thereof.
    Type: Grant
    Filed: January 26, 2007
    Date of Patent: July 20, 2010
    Assignee: Aventis Pharma S.A.
    Inventors: Hartmut Strobel, Sven Ruf, Dominique Lesuisse, Conception Nemecek, Youssef El-Ahmad, Stefan Guessregen, Anne Lebrun, Kurt Ritter, Didier Benard, Augustin Hittinger, Hervé Bouchard
  • 4-benzimidazol-2-ylpyridazin-3-one derivatives
    Patent number: 7754713
    Abstract: Disclosed are compounds of the general formula (I), where the definition of the substituents A, B, D, E, R1 and R2 are detailed in the description, and the physiologically tolerated salts thereof, a process for the preparation of these compounds and their use as pharmaceuticals. These compounds are kinase inhibitors, in particular inhibitors of the kinase CDK2 (cyclin-dependent kinase 2).
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: July 13, 2010
    Assignee: Aventis Pharma S.A.
    Inventors: Swen Hoelder, Karl Schoenafinger, David William Will, Hans Matter, Gunter Muller, Cecile Combeau, Christine Delaisi, Anke Steinmetz, Ingrid Sassoon
  • NOVEL PROCESS FOR THE PREPARATION OF CHIRAL COMPOUNDS DERIVED FROM HEXANOIC ACID ESTERS AND INTERMEDIATES USED IN THE SYNTHESIS OF CHIRAL-2-(BROMOMETHYL)-2-ETHYLHEXANOIC ACID
    Publication number: 20100160670
    Abstract: The present invention comprises a novel process for the preparation of a chiral compound of formula (I) wherein R1 is hydroxyl or a group which activates the carboxyl and R2 is alkyl optionally substituted by halogen or benzyl, its preparation, its application in the synthesis of chiral 2-bromomethyl-2-ethylhexanoic acid and novel intermediates.
    Type: Application
    Filed: March 4, 2010
    Publication date: June 24, 2010
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Veronique Crocq-Stuerga, Patrick Roussel
  • ANTITUMOUR COMBINATIONS CONTAINING A VEGF INHIBITING AGENT AND IRINOTECAN
    Publication number: 20100160233
    Abstract: Disclosed are antitumor combinations of VEGF inhibitors with Irinotecan and the use thereof in the treatment of neoplastic diseases.
    Type: Application
    Filed: January 4, 2010
    Publication date: June 24, 2010
    Applicant: Aventis Pharma S.A.
    Inventors: Marie-Christine BISSERY, Marielle CHIRON-BLONDEL, Pascale LEJEUNE, Patricia VRIGNAUD
  • Pharmacological uses of azetidine derivatives
    Patent number: 7741316
    Abstract: A method of treating or preventing Alzheimer's disease, Parkinson's Disease and/or schizophrenia, this method comprising administering to a patient in need of such treatment a compound of formula: in which R, R3 and R4 are as defined in the specification.
    Type: Grant
    Filed: November 12, 2004
    Date of Patent: June 22, 2010
    Assignee: Aventis Pharma S.A.
    Inventors: Daniel Achard, Herve Bouchard, Jean Bouquerel, Bruno Filoche, Serge Grisoni, Augustin Hittinger, Michael R. Myers
  • Heterocyclic compounds, their preparation and their use as medicaments, in particular as anti-bacterial agents
    Patent number: 7732610
    Abstract: The invention relates to new heterocyclic compounds of general formula (I), and their salts with a base or an acid: The invention also relates to a process for the preparation of these compounds as well as their use as medicaments, in particular as anti-bacterial agents.
    Type: Grant
    Filed: February 6, 2006
    Date of Patent: June 8, 2010
    Assignee: Aventis Pharma S.A.
    Inventors: Maxime Lampilas, Jozsef Aszodi, David Alan Rowlands, Claude Fromentin
  • YEAST STRAINS AUTONOMOUSLY PRODUCING STEROIDS
    Publication number: 20100112634
    Abstract: The present invention relates to genetically modified yeast strains autonomously producing, from a simple carbon source, steroids. The invention also relates to a method for producing steroids from such yeast strains.
    Type: Application
    Filed: January 7, 2010
    Publication date: May 6, 2010
    Applicant: AVENTIS PHARMA S.A.
    Inventors: Roberto SPAGNOLI, Tilman ACHSTETTER, Gilles CAUET, Eric DEGRYSE, Bruno DUMAS, Denis POMPON, Jacques WINTER